Infectious Diseases, A Resurgent Problem: Developing Effective Public Health Responses

Emerging Infectious Diseases and the Threat to Occupational Health in the U.S. and Canada

Volumn , Issue , 2006, Pages 221-238

  Avery, George ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84957110914     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9781420006049-12     Document Type: Chapter

References (161)

1. D. A. Henderson, “Surveillance Systems and Intergovernmental Cooperation,” in Emerging Viruses, ed. S. S. Morse (New York: Oxford University Press; 1993), 283–89.
2. A. Benenson, “Infectious Diseases,” in Epidemiology and Health Policy, ed. S. Levine and A. M. Lilienfield (New York: Tavistock, 1987), 207–26.
3. M. J. Roseneau, “The Uses of Fear in Preventive Medicine,” Boston Medical and Surgical Journal 162, no. 10 (1910):305–07.
4. B. Frist, “Manhattan Project for the 21st Century,” Paper presented at Harvard Medical School Health Care Policy Seidman Lecture, June 1, 2005, Cambridge, MA.
5. R. L. Berkelman et al., “Infectious Disease Surveillance: A Crumbling Foundation” Science 264, no. 5157 (1994):368–70.
6. E. Fee and T. M. Brown, “The Unfulfilled Promise of Public Health: Deja Vu All Over Again,” Health Affairs 21, no. 6 (2002):31–43.
7. M. Drexler, Secret Agents: The Menace of Emerging Infections (Washington, D.C.: Joseph Henry Press, 2002).
8. Committee for the Study of the Future of Public Health, The Future of Public Health (Washington, D.C.: National Academy Press, 1988).
9. L. J. Letgers et al., “Are We Prepared for a Viral Pandemic Emergency?” in Emerging Viruses, ed. S. S. Morse (New York: Oxford University Press, 1993).
10. W. R. Dowdle “The Future of the Public Health Laboratory,” Annual Review of Public Health 14 (1993): 649–64.
11. Berkelman et al., “Infectious Disease Surveillance.”
12. J. Lederberg ed. Microbial Threats to Health in the United States (Washington, D.C.: National Academy Press, 1992).
13. U. Desselberger, “Emerging and Re-emerging Infectious Diseases,” Journal of Infection 40, no. 1(2000):3–15.
14. H. Feldman et al., “Emerging and Re-Emerging Infectious Diseases,” Medical Microbiology and Immunology 191 (2002):63–74.
15. D. G. Maki, “SARS Revisited: The Challenge of Contr olling Emerging Infectious Diseases at the Local, Regional, Federal, and Global Levels,” Mayo Clinic Proceedings 79, no. 11 (2004):1359–66.
16. Berkelman et al., “Infectious Disease Surveillance.”
17. V. Sidel, H. Cohen, and R. Gould, “Good Intentions and the Road to Bioterrorism Preparedness,” American Journal of Public Health 91, no. 5 (2001):716–18.
18. J. D. Mayer “Geography, Ecology, and Emerging Infectious Disease,”Social Science and Medicine 50 (2000):937–52.
19. P. R. Epstein, “Climate Change and Emerging Infectious Diseases,” Microbes and Infection 3 (2001): 747–54.
20. S. S. Morse, “Examining the Origins of Emerging Viruses,” in Emerging Viruses, ed. S. S. Morse (New York: Oxford University Press, 1993).
21. L. Garrett, The Coming Plague: Newly Emerging Diseases in a World Out of Balance (New York: Farrar, Strauss, and Giroux, 1994).
22. M. Shnayerson and M. J. Plotkin, The Killers Within: The Deadly Rise of Drug Resistant Bacteria (Boston: Back Bay Books, 2002).
23. R. H. Kahn et al., “Syphilis Outbreaks Among Men Who Have Sex With Men,” Sexually Transmitted Diseases 29, no. 5 (2002):285–87.
24. A. Trampuz et al., “Avian Influenza: A New Pandemic Threat?” Mayo Clinic Proceedings 79, no. 4 (2004):523–30.
25. M..J. Earls and S. A. Hearne. Facing the Flu: From the Bird Flu to a Possible Pandemic, Why Isn’t America Ready? (Washington, D.C.: Trust for America’s Health, 2004).
26. H. G. Stiver “The Threats and Prospects for Control of an Influenza Pandemic,” Future Drugs 3, no. 1 (2004):35–42.
27. M. A. Hamburg, “Public Health Preparedness,” Science 295, no. 5559 (2002).
28. A. Fine and M. Layton, “Lessons From the West Nile Viral Encephalitis Outbreak in New York City, 1999: Implications for Bioterrorism Preparedness,” Clinical Infectious Diseases 32, no. 2 (2001):277–82.
29. H. L. Hinton, Combating Terrorism: Considerations for Investing Resources in Chemical and Biological Preparedness (Washington, D.C.: General Accounting Office, 2001).
30. A.E. Smithson and L-A. Levy, Ataxia: The Chemical and Biological Terrorism Threat and the US Response (Washington, D.C.: The Henry L. Stimson Center, 2000).
31. E. L. Baker et al., “The Public Health Infrastructure and Our Nation’s Health,” Annual Reviews in Public Health 26 (2005):203–318.
32. M. L. Boulton et al., “Assessment of Epidemiologic Capacity in State and Territorial Health Departments — United States, 2001,” Morbidity and Mortality Weekly Report 52, no. 43 (2003):1049–51.
33. R. E. Hoffman et al., “Capacity of State and territorial health Agencies to Prevent Foodborne Illness,” Emerging Infectious Diseases 11, no. 1 (2005):11–16.
34. S. Smith, “Anthrax vs. the Flu,” International Journal of Health Services 34, no. 1 (2004):169–72.
35. K. Eban “Waiting for Bioterror: Is Our Public Health System Ready?” The Nation 275, no. 20 (2002):11.
36. C. Keane et al., “Services Privatized in Local Health Departments: A National Survey of Practices and Perceptions,” American Journal of Public Health 92, no. 8 (2002):1250–53.
37. J. Heinrich, Bioterrorism: Review of Public Health Preparedness Programs (Washington, D.C.: General Accounting Office, 2001).
38. General Accounting Office, West Nile Virus Outbreak: Lessons for Public Health Preparedness (Washington, D.C.: General Accounting Office, 2000).
39. J. L. Pressman and A. B. Wildavsky, Implementation: How Great Expectations in Washington Are Dashed in Oakland; Or, Why It’s Amazing that Federal Programs Work at All, This Being a Saga of the Economic Development Administration as Told by Two Sympathetic Observers Who Seek to Build Morals on a Foundation of Ruined Hopes (Berkeley: University of California Press, 1973).
40. J. G. March and J. P. Olsen, “Garbage-Can Models of Decision-making in Organizations,” in Ambiguity and Command: Organizational Perspectives on Military Decision-Making, ed. J. G. Marsh and S. Weissinger-Baylon (Marshfield, MA: Pittman; 1986).
41. S. Weissinger-Baylon, “Garbage Can Processes in Naval Warfare,” in Ambiguity and Command: Organizational Perspectives on Military Decision-Making, ed. J. G. March and S. Weissinger-Baylon (Marshfield, MA: Pittman, 1986).
42. J. G. March and J. P. Olsen, Rediscovering Institutions: The Organizational Basis of Politics (New York: The Free Press, 1989), 21–38.
43. B. T. Pentland and H. R. Rueter, “Organizational Routines as Grammars of Action,” Administrative Science Quarterly 39 (1994):484–510.
44. S. A. Kauffman, The Origins of Order: Self Organization and Selection in Evolution (New York: Oxford University Press, 1993).
45. J. G. March and H. A. Simon, Organizations (New York: John Wiley, 1967).
46. J. Von Neumann and O. Morgenstern, Theory of Games and Economic Behaviour (Princeton, NJ: Princeton University Press, 1944).
47. W. B. Arthur “Inductive Reasoning and Bounded Rationality,”American Economic Review 84, no. 2 (1994):406–11.
48. L. Cosmides and J. Tooby, “Better Than Rational: Evolutionary Psychology and the Invisible Hand,” American Economic Review 84, no. 2 (1994):327–32.
49. P. t’Hart, U. Rosenthal, and A. Kouzmin, “Crisis Decision-Making: The Centralization Theory Revisited,” Administration and Society 25, no. 1 (1993):12–45.
50. G. T. Allison, “Conceptual Models and the Cuban Missile Crisis,” American Political Science Review 63 (1969): 689–718.
51. F. D. Scutchfield, E. A. Knight, A. V. Kelly, M. W. Bhandari, and I. P. Vasilescu, “Local Public Health Agency Capacity and Its Relationship to Public Health System Performance,” Journal of Public Health Management Practice 10, no. 3 (2004):204–15.
52. S. A. McCann, “View from the Hill: Congressional Efforts to Address Bioterrorism,”Emerging Infectious Diseases 5, no. 4 (1999):496.
53. Committee for the Study of Public Health, 1988, 83–86.
54. M. A, Hamburg and S. A. Hearne, SARS and Its Implications for U.S. Public Health Policy - “We’ve Been Lucky” (Washington, D.C.: Trust for America’s Health, 2003).
55. L. D. Weiss, Private Medicine and Public Health (Boulder, CO: Westview Press, 1997).
56. L. O. Gostin, Public Health Law: Power, Duty, and Restraint (Berkeley: University of California Press, 2000).
57. J. W. Kingdon, Agendas, Alternatives, and Public Policies, 2nd ed. (New York: Longman, 2002).
58. C. H. Foreman, Plagues, Products, and Politics: Emergent Public Health Hazards and National Policymaking (Washington, D.C.: Brookings Institute, 1994).
59. Centers for Disease Control, Preventing Emerging Infections: A Strategy for the 21st Century (Atlanta, GA: Centers for Disease Control and Prevention, 1998).
60. Centers for Disease Control, “The Centers for Disease Control and Prevention on Emerging Infectious Disease Threats,” Population and Development Review 20, no. 3 (1994):687–90.
61. M. T. Osterholm, “Bioterrorism: Media Hype or Real Potential Nightmare?” American Journal of Infection Control 27, no. 6 (1999):461–62.
62. R. Katz, “Public Health Preparedness: The Best Defense Against Biological Weapons,” The Washington Quarterly 25, no. 3 (2002):69–82.
63. J. L. Bryan and H. F. Fields, “An Ounce of Prevention is Worth a Pound of Cure - Shoring Up the Public Health Infrastructure to Respond to Bioterrrorist Attacks,” American Journal of Infection Control 27, no. 6 (1999):465–67.
64. J. E. McDade, “Addressing the Potential Threat of Bioterrorism — Value Added to an Improved Public Health Infrastructure,” Emerging Infectious Diseases 5, no. 4 (1999):591–92.
65. G. Avery, “Bioterrorism, Fear, and Public Health Reform: Matching a Policy Solution to the Wrong Window,” Public Administration Review 64, no. 3 (2004):275–88.
66. H. J. Geiger, “Terrorism, Biological Weapons, and Bonanzas: Assessing the Real Threat to Public Health,” American Journal of Public Health 91, no. 5 (2001):708–09.
67. V. W. Sidel et al. “Bioterrorism Preparedness: Cooptation of Public Health?” Medicine and Global Survival 7, no. 2 (2002):82–89.
68. N. Ward et al., “Policy Framing and Learning the Lessons from the UK’s Foot And Mouth Disease Crisis,” Environmental and Planning C: Government and Policy 22 (2004): 291–306.
69. Drexler, Secret Agents, 267–68.
70. M. T. Osterholm and J. Schwartz, Living Terrors: What America Needs to Know to Survive the Coming Bioterrorism Catastrophe (New York: Delacorte Press, 2000).
71. L. Garrett, “Responding to the Nightmare of Bioterrorism,” The Responsive Community 12, no.1 (2002):88–93.
72. Geiger, “Terrorism, Biological Weapons.”
73. S. A. Hearne et al., Ready or Not? Protecting the Public’s Health in the Age of Bioterrorism (Washington, D.C.: Trust for America’s Health, 2004).
74. Garrett, “Responding to the Nightmare.”
75. Sidel et al., “Bioterrorism Preparedness,” 29.
76. W. L. Waugh and R. T. Sylves, “Organizing the War on Terror,” Public Administration Review 62, Suppl. 1 (2002):145–53.
77. D. P. Moyhnihan, Secrecy (New Haven, CT: Yale University Press, 1998).
78. t’Hart et al., “Crisis Decision-Making.”
79. M. Siegel, “The Anthrax Fumble: Bureaucratic Timididty and Turf Battles Needlessly Put Many Americans at Risk.” The Nation 274, no.10 (2002):14.
80. P. K. Dewan et al., “Inhalational Anthrax Outbreak Among Postal Workers, Washington, DC: 2001,” Emerging Infectious Diseases 8, no. 10 (2002): 1066–72.
81. R. A. Falkenrath et al., America’s Achilles Heel: Nuclear, Biological, and Chemical Terrorism and Covert Attack (Cambridge, MA: MIT Press, 1998).
82. S. Brownlee “Under Control — Why America Isn’t Ready for Bioterrorism,” The New Republic (2001):22–24.
83. M. K. Wynia and L. O. Gostin, “Ethical Challenges in Preparing for Bioterrorism: Barriers Within the Health Care System,” American Journal of Public Health 94, no.7 (2004):1096–1102.
84. M. K. Wynia and L. Gostin, “The Bioterrorist Threat and Access to Healthcare,” Science 296, no.5573 (2002).
85. J. Lederberg, “Concluding Remarks,” in Managed Care Systems and Emerging Infections: Challenges and Opportunities for Strengthening Surveillence, Research, and Prevention, Workshop Summary, ed. J. R. Davis (Washington, D.C.: National Academy Press; 2000), 76–77.
86. N. Pourat et al., “Medicaid Managed Care and STDs: Missed Opportunities to Control the Epidemic,” Health Affairs 21, no. 3 (2002):228–39.
87. H. E. Frech, “Physician Fees and Price Controls,” in American Health Care: Government, Market Processes, and Public Health, ed. R. D. Feldman (Oakland, CA: The Independent Institute; 2000), 347–63.
88. W. Higgins et al., “Assessing Hospital Preparedness Using an Instrument Based on the Mass Casualty Disaster Plan Checklist: Results of a Statewide Survey” American Journal of Infection Control 32 (2004):327–32.
89. J. R. Richards et al., “Survey of Directors of Emergency Departments in California on Overcrowding,”Western Journal of Medicine 172 (2000):385–88.
90. R. W. Derlet et al., “Frequent Overcrowding in US Emergency Departments,” Academic Emergency Medicine 8, no. 2 (2001):151–55.
91. J. Heinrich et al., Infectious Disease Outbreaks: Bioterrorism Preparedness Efforts Have Improved Public Health Response Capacity, But Gaps Remain (Washington, D.C.: General Accounting Office, 2003).
92. J. G. Bartlett, “Decline in Microbial Studies for Patients With Pulmonary Infections,” Clinical Infectious Diseases 39 (2004):170–72.
93. D. Hanflinget al., “Making Healthcare Preparedness a Part of the Homeland Security Equation,”Topics in Emergency Medicine 26, no. 2(2004):128–42.
94. D. C. Wetteret al., “Hospital Preparedness for Victims of Chemical or Biological Terrorism,” American Journal of Public Health 91, no. 5 (2001):710–16.
95. W. R. Jarvis, “Infection Control and Changing Health-Care Delivery Systems,” Emerging Infectious Diseases 7, no.2 (2001):170–73.
96. N. Lurie, “Perspective: The Public Health Infrastructure: Rebuild Or Redesign?” Health Affairs21, no. 6 (2002):28–30.
97. J. G. Wheeler et al., “Barriers to Public Health Management of a Pertussis Outbreak in Arkansas,”Archives of Pediatric and Adolescent Medicine 158, no. 2 (2004):146–52.
98. S. C., Alder et al., “Physician Preparedness for Bioterrorism Recognition and Response: A Utah-Based Needs Assessment,” Disaster Management and Response2, no. 3 (2004):69–74.
99. N. C. Mann et al., “Public Health Preparedness for Mass Casualty Events: A 2002 State-by-State Assessment,” Prehospital and Disaster Medicine 19, no. 3(2004):245–55.
100. D. N. Fox, “From AIDS to TB: Value Conflicts in Reporting Diseases,” Hastings Center Reports 11 (1986):L11–L16.
101. Wynia et al., “Bioterrorist Threat.”
102. C. R. Wise and R. Nader, “Organizing the Federal System for Homeland Security: Problems, Issues, and Dilemmas,” Public Administration Review 62, Suppl. 1 (2002):44–58.
103. J. Kayyem, US Preparations for Biological Terrorism: Legal Limitations and the Need for National Planning Cambridge, MA: Harvard University, John F. Kennedy School of Government, 2001.
104. L. O. Gostin et al., “The Model State Emergency Health Powers Act: Planning for and Response to Bioterrorism and Naturally Occurring Infections,” Journal of the American Medical Association 288, no. 5 (2002):622–28.
105. J. Kincaid and R. L. Cole, “Issues of Federalism in Response to Terror,”Public Administration Review 62, Suppl. 1(2002):181–92.
106. J. Colgrove and R. Bayer, “Manifold Restraints: Liberty, Public Health, and the Legacy of Jacobsen v. Massachusetts,” American Journal of Public Health 95, no. 4 (2005): 571–76.
107. W. K. Mariner et al., “Jacobsen v Massachusetts: It’s Not Your Great-Great- Grandfather’s Public Health Law,” American Journal of Public Health 95, no. 4 (2005):581–90.
108. L. O. Gostin, “Influenza Pandemic Preparedness: Legal and Ethical Dimensions,” Hastings Center Report 34, no. 5 (2004):10–11.
109. G. J. Annas, “Perspective: Bioterrorism, Public Health, and Human Rights,” Health Affairs; 21, no.6 (2002) 94–97.
110. A. Etzioni, “Perspective: Public Health Law: A Communitarian Perspective,” Health Affairs; 21, no. 6 (2002):102–04.
111. R. Addlakha, “State Legitimacy and Social Suffering in a Modern Epidemic: A Case Study of Dengue Hemmorhagic Fever in Delhi,” Indian Sociology; 35, no. 2 (2001):151–79.
112. B. D. Stein et al., “Emotional and Behavioral Consequences of Bioterrorism: Planning a Public Health Response,” The Millbank Quarterly 82, no. 3 (2004):413–56.
113. R. J. Wray et al., “Theoretical Perspectives on Public Communication Preparedness for Terrorist Attacks,” Family and Community Health; 27, no. 3 (2004):232–41.
114. Fine and Layton, “Lessons from West Nile,” 105.
115. A. S. Khan and D. A. Ashford, “Ready or Not — Preparedness for Bioterrorism,” New England Journal of Medicine; 345, no. 4 (2001): 287–89.
116. Adler et al., “Physician Preparedness.”
117. J. W. Buehler, “Surveillence,” in Rothman KJ, Greenland S, editors. Modern Epidemiology, 2nd ed., K. J. Rothman and S. Greenland (Philadelphia, PA: Lippincott, Williams, and Wilkins, 1998), 435–57.
118. Foreman et al., “Plagues, Products, Politics,” 146–49.
119. D. L. Heymann and G. R. Rodier, “The WHO Operational Support Team to the Global Outbreak Alert and Response Network. Hot Spots in a Wired World: WHO Surveillence of Emerging and Re-Emerging Infectious Diseases,” The Lancet Infectious Diseases; 1 (2001): 345–53.
120. Berkelman et al., “Infectious Disease Surveillance.”
121. J. W. Buehler, “Review of the 2004 National Syndromic Surveillence Conference - Lessons Learned and Questions To Be Answered,” Morbidity and Mortality Weekly Report; 53, Suppl. (2004):18–22.
122. J. A. Pavin et al., “Innovative Surveillence Methods for Rapid Detection of Disease Outbreaks and Bioterrorism: Results of an Interagency Workshop on Health Indicator Surveillence,” American Journal of Public Health; 93, no. 8 (2003):1230–35.
123. J. M. Townes et al., “Investigation of an Electronic Emergency Department Information System as a Data Source for Respiratory Syndrome Surveillance,” Journal of Public Health Management Practice; 10, no. 4 (2004):299–307.
124. C. V. Broome and J. Loonsk, “Public Health Information Network Improving Early Detection by Using a Standards-Based Approach to Connecting Public Health and Clinical Medicine” Morbidity and Mortality Weekly Report; 53, Suppl. (2004):199–202.
125. D. M. Bravata et al., “Systematic Review: Surveillance Systems for Early Detection of Bioterrorism-Related Diseases,” Annals of Internal Medicine; 140, no. 11 (2004):910–22.
126. D. Koo, “Managed Care and Infectious Disease Surveillance: Opportunities for Collaboration,” in Managed Care Systems and Emerging Infections: Challenges and Opportunities for Strengthening Surveillence, Research, and Prevention, Workshop Summary, ed. J. R. David (Washington, D.C.: National Academy Press, 2000).
127. R. Platt, “Collaborative Surveillance Efforts and Monitoring of Data,” in Managed Care Systems and Emerging Infections: Challenges and Opportunities for Strengthening Surveillence, Research, and Prevention, Workshop Summary, ed. J. R. Davis (Washington, D.C.: National Academy Press, 2000).
128. D. F. Gordon and D. G. F. Noah, The Global Infectious Disease Threat and Its Implications for the United States (Langley, VA: Central Intelligence Agency, 2000).
129. J. Heinrich et al., Gaps Remain in Surveillance Capabilities of State and Local (Washington, D.C.: General Accounting Office, 2003).
130. D. Drociuk et al., “Health Information Privacy and Syndromic Surveillance Systems,” Morbidity and Mortality Weekly Report; 53, Suppl. (2004): 221–25.
131. D. M. Sosin and J. DeThomasis, “Evaluation Challenges for Syndromic Surveillance,” Morbidity and Mortality Weekly Report 53, Suppl. (2004): 125–29.
132. T. Zwilich, “Lawmakers Urge Bioterror, Disease Surveillance Law,” Reuters (2003).
133. M. Lipsky, “Street Level Bureaucracy and the Analysis of Urban Reform,” Urban Affairs Quarterly 6 (1971):391–409.
134. B. Hjern, “Implementation Research: The Link Gone Missing,” Journal of Public Policy 2 (1982):301–08.
135. E. Ostrom, “The Danger of Self-Evident Truths,” PS — Political Science and Politics; 33, no. 1 (2000):33–44.
136. McHugh et al., “How Prepared are Americans for Public Health Emergencies? Twelve Communities Weigh In,” Health Affairs; 23, no. 3 (2004):201–09.
137. Z. Bashir et al., “Local and State Collaboration for Effective Preparedness Planning,” Journal of Public Health Management Practice 9, no.5 (2003): 344–51.
138. “Smallpox Fiasco,” The Washington Post, 2003. p. A20.
139. S. A. Hearne et al., Public Health Laboratories: Unprepared and Overwhelmed. (Washington, D.C.: Trust for America’s Health, 2003).
140. L. A. Cole, “Risks of Publicity about Bioterrorism: Anthrax Hoaxes and Hype,” American Journal of Infection Control;27, no. 6 (1999):470–73.
141. W. A. Orenstein et al., “Immunizations in the United States: Success, Structure, and Stress,” Health Affairs; 24, no. 3 (2005): 599–610. 155. Benenson, “Infectious Diseases.”
142. National Vaccine Advisory Committee, “Strengthening the Supply of Routinely Recommended Vaccines in the United States: Recommendations From the National Vaccine Advisory Committee,” Journal of the American Medical Association; 290 no. 23 (2003): 3122–28.
143. P. A. Offit, “Why Are Pharmacuetical Companies Gradually Abandoning Vaccines?” Health Affairs;24, no. 3 (2005):622–30.
144. I. D. Gus et al., “Planning for the Next Pandemic of Influenza,” Reviews in Medical Virology 11 (2001): 59–70.
145. J. E. Calfee, Bioterrorism and Pharmacueticals: The Influence of Secretary Thompson’s Cipro Negotiations (Washington, D.C.: American Enterprise Institute, 2001).
146. Gust et al., “Planning for the Next Pandemic.”
147. P. A. Offit and R. K. Jew, “Addressing Parents’ Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?” Pediatrics; 112, no. 6 (2003): 1394–401.
148. Stiver, “Threats and Prospects.”
149. Gust et al., “Planning for the Next Pandemic.”
150. R. J. Webby and R. G. Webster, “Are We Ready for Pandemic Influenza?” Science; 302, no. 5650(2003): 1519-22.
151. D. Carpenter, “The Political Economy of FDA Drug Review: Processing, Politics, and Lessons for Policy,” Health Affairs; 23, no. 1 (2004):52–63.
152. S. A. Plotkin, “Why Certain Vaccines Have Been Delayed or Not Developed at All,” Health Affairs; 24, no. 3 (2005): 631–34.
153. P. Ritvo et al., “Vaccines in the Public Eye,” Nature Medicine; 11, 4 Suppl. (2005): S20–S24.
154. P. F. Harrison and J. Lederberg, eds., Antimicrobial Resistance: Issues and Options (Washington, D.C.: National Academy Press, 1998).
155. Alder et al., “Preparedness for Bioterrorism Recognition and Response.”
156. A. S. Fauci et al., “Emerging Infectious Diseases: A 10-Year Perspective From the National Institute of Allergy and Infectious Diseases,” Emerging Infectious Diseases 11, no. 4 (2005): 519–25.
157. R. G. Ridley, “Research on Infectious Disease Requires Better Coordination,” Nature Medicine;10, 12 Suppl. (2004): S137–S40.
158. J. Heinrich, Bioterrorism: Public Health and Medical Preparedness (Washington, D.C.: General Accounting Office, 2001).
159. L. P. Cohen, “Safe and Effective: Many Medicines Remain Potent for Years Past Their Expiration Dates,” Wall Street Journal.
160. Smithson and Levia, Atazia, 261–62, 296–98.
161. G. Avery, “Public Health System Has Foot in Mouth,”Washington Times.